A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.Ian W. Flinn, Albert S. Yu, L. L. Miller et al.|Journal of Clinical Oncology|2011Cited by 18
Mo1467: HISTOLOGICAL REVISION OF HIGH-GRADE DYSPLASIA IN IBD IMPACTS THE RATE OF ADVANCED NEOPLASIA RECURRENCE: A RETROSPECTIVE COHORT STUDYMaarten te Groen, Frank Hoentjen, Monica E. Derks et al.|Gastroenterology|2022Cited by 0
Anti-Contactin-1 Associated Membranous Nephropathy Presenting With Subsequent Autoimmune NodopathyRuben Visch, Anne-Els van de Logt, Hanna Dêbiec et al.|Kidney Medicine|2026Cited by 0